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Abstract 
Background: Cost-effectiveness analysis provides a crucial means for evidence-informed decision-making on 
resource allocation. This study aims to elicit individuals’ willingness to pay (WTP) for one additional quality-adjusted 
life-year (QALY) gained from life-saving treatment and associated factors in Kermanshah city, western Iran.
Methods: We conducted a cross-sectional study on a total of 847 adults aged 18 years and above to elicit their WTP 
for one additional QALY gained by oneself and a family member using a hypothetical life-saving treatment. We used a 
multistage sampling technique to select the samples, and the Iranian version of EQ-5D-3L, and visual analogue scale 
(VAS) measures to obtain the participants’ health utility value. The Tobit regression model was used to identify the fac-
tors affecting WTP per QALY values.
Results: The mean WTP value and standard deviation (SD) was US$ 862 (3,224) for the respondents. The mean utility 
values using EQ-5D-3L and VAS methods for respondents were 0.779 and 0.800, respectively. Besides, the WTP for the 
additional QALY gained by the individual participants using the EQ-5D-3L and VAS methods were respectively US$ 
1,202 and US$ 1,101, while the estimated value of the family members was US$ 1,355 (SD = 3,993). The Tobit regres-
sion models indicated that monthly income, education level, sex, and birthplace were statistically significantly associ-
ated (p < 0.05) with both the WTP for the extra QALY values using the EQ-5D-3L and the VAS methods. Educational 
level and monthly income also showed statistically significant relationships with the WTP for the additional QALY 
gained by the family members (p < 0.05).
Conclusion: Our findings indicated that the participants’ WTP value of the additional QALY gained from the hypo-
thetical life-saving treatment was in the range of 0.20–0.24 of the gross domestic product (GDP) per capita of Iran. This 
value is far lower than the World Health Organization (WHO) recommended CE threshold value of one. This wide gap 
reflects the challenges the health system is facing and requires further research for defining the most appropriate CE 
threshold at the local level.
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Background
The scarcity of healthcare resources and the increasing 
clients’ treatment demands challenge the decisions on 
resource allocation such as financial reimbursements, 
especially in the health systems of resource-constrained 
countries [1, 2]. The incremental cost-effectiveness ratio 
(ICER) can be applied to compare the costs and health 
gains from two or more alternative interventions and is 
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a widely used to handle challenging decisions [3–5]. The 
quality-adjusted life years (QALY), which includes both 
the quality and quantity of life, is one of the commonly 
used health outcome indicators, and the cost per QALY 
is a ratio of the additional cost per QALY gained [6, 7]. 
One QALY equates to one year in perfect health. An 
intervention is considered cost-effective [7] if the ICER 
value lies below an established threshold value, and vice 
versa [5, 8]. Despite this commonly used approach, there 
is no single standard to estimate the CE threshold [9]. 
The World Health Organization (WHO) considers that if 
the incremental cost to incremental QALYs gained ratio 
is less than one, or a value of one to three times the per 
capita GDP as cost-effective intervention, with the higher 
value unacceptable [10, 11].
A recent study that estimated the CE threshold indi-
cated the WHO recommended threshold value is con-
siderably higher for the low-middle income countries 
(LMICs) [12]. Because of the limitation of the WHO 
recommended estimation, others applied the willing-
ness to pay (WTP) method for a preferred attribute 
to estimate the CE threshold value [5, 13–15]. Despite 
methodological issues related to the use of CE threshold 
value approaches, there is a consensus that the different 
thresholds should be well defined and used for different 
situations such as with quality of life-improving or life-
threatening conditions. Evidence indicates a higher WTP 
values for life-saving interventions than for quality of 
life-improving ones [16]. Others also reported different 
QALY values for different health status, and those with 
worse health status had a higher value than those with 
better health status [13].
In Iran’s health system, there seems to be a consensus 
in using a regional CE threshold to maximize health and 
efficiency. Some of the efforts demonstrating the use of 
the CE threshold are in the establishment of the Health 
Technology Analysis Office at the Ministry of Health 
and Medical Education (MoHME) of Iran in 2007, and; 
in the provision of training in the fields of health eco-
nomics, health technology assessment, and pharmaco-
economics in medical universities. Other efforts include 
the application of pharmaco-economic evaluation guide-
lines to include new drugs in the national drug list of the 
Food and Drug Administration of Iran, and the conduct 
of studies on economic evaluations concerning medical 
equipment and treatment are additional national-level 
efforts [17–19].
Despite the absence of clear valid criteria for the CE 
threshold to aid in the decision on health resources allo-
cation, the decision-makers in Iran are implicitly apply-
ing the WHO recommendation of choosing the CE 
intervention(s) which has its limitations [2]. Besides, 
the use of the WHO criteria on the decisions made 
concerning the health insurance organizations’ benefits 
such as inclusion and exclusion healthcare is unclear. 
However, a study in Tehran reported an average WTP per 
QALY of the participants ranging from US$ 1,032 to US$ 
2,666. These minimum and maximum values accounted 
for 0.22 to 0.56 GDP per capita of Iran in 2014 [2]. Never-
theless, to the best of our knowledge, little information is 
available on the monetary value of life-saving treatments 
and associated factors in Iran. Thus, to fill this informa-
tion gap, this research strove to answer the following 
three main questions: What is the maximum WTP of a 
participant for one additional QALY from a hypotheti-
cal life-saving treatment? What is the maximum WTP of 
a participant if the gain in one additional QALY is for a 
family member? Finally, are these values associated with 
the explanatory variables included in the study? Elicit-
ing the monetary value of the QALY as the threshold in 
CE analysis can provide useful information for evidence-
informed decisions in resource allocation in Iran, and 
perhaps in other similar contexts.
Methods and materials
Setting
Kermanshah city, the capital of Kermanshah province, 
is located in western Iran. Based on the 2016 population 
census of Iran, the city had a total population of about 
two million people. The socio-economic status of the 
people is low, and the city’s contribution to the national 
gross domestic product (GDP) is only about 1.7% to 2%.
Study design, study period, and sample size
A cross-sectional study was conducted on a total sample 
of 943 adults aged 18 years and above, from the general 
population of Kermanshah city, to elicit their WTP for 
one additional QALY gained from a hypothetical life-
saving treatment during September to December 2019. 
The Mitchell and Carson [20] was used to determine the 
appropriate sample size.
where n represents the calculated sample size at α=10%, 
V = 2.5, and  = 0.1 (the difference between the true and 
estimated WTP values). Thus, the computed sample size 
was at 786. However, considering the attrition rate of 20% 
and generalizability of the findings, the final sample for 
the study was 943. We used a multistage sampling tech-
nique to select the study participants by dividing the city 
into the western, eastern, central, northern, and southern 
geographic areas. Then, we equally divided the final sam-
ple into five (n = 189) and selected the study participants 
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Data collection and variables
We used a self-administrated questionnaire to obtain 
data for eliciting the participants’ WTP for one additional 
QALY gained by oneself and a family member using a 
hypothetical life-saving treatment [4]. The self-adminis-
tered questionnaire focused on the participants’ current 
health state, WTP for one additional QALY gained from 
life-saving treatment, and sociodemographic characteris-
tics (Additional file 1: Appendix 1). Before the final data 
collection, five health economists checked the question-
naire for its content validity, a revision was made based 
on their opinions, and a pilot test was conducted on 30 
participants to ensure the understandability of the ques-
tions and the hypothetical scenarios.
We used the Iranian version of the EQ-5D-3L as well 
as a visual analogue scale (VAS) measure to obtain the 
respondents’ health utility values [4]. The EQ-5D-3L 
had five dimensions consisting of mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression 
dimensions with; three-level responses of: no problems, 
some problems, and extreme problems. A participant had 
to use one of these responses in each dimension to indi-
cate his/her current health state [21]. Again, we allowed 
the respondents to identify their current health state on 
a 100-unit thermometer analogue scale extending from 0 
(almost dead) to 100 (perfect health) for the VAS valua-
tion [4, 22].
As in a previous study [4], we used two hypothetical 
life-threatening condition for the individual participants 
and their family members to estimate their maximum 
WTP value for one additional QALY gained. The assump-
tion used for the participant in the first scenario was as 
follows: “Suppose you had a life-threatening disease for 
the past year. There is a cure (treatment) for the disease., 
and if you do not get the treatment now, you will die today. 
If you get treated, you will be back to your original health 
state and live only for one more year”. In the second sce-
nario, we presented the respondents with a similar to the 
first one but asked them to imagine the situation for his/
her family members (a different perspective).
We elicited the maximum WTP value for one more 
QALY gained by a family member from the hypotheti-
cal intervention using the contingent valuation method 
(CVM) [23]. The CVM is one of the most commonly 
employed methods to elicit the WTP of individuals for 
one additional QALY gained using an intervention. For 
example, a systematic review that determined the WTP 
per QALY reported that 92.85% of the studies applied the 
CVM, and only one study used a discrete choice experi-
ment method to estimate the WTP of participants [16]. 
Furthermore, we used the payment card (PC) method, 
one of the CVM methods, accompanied by a follow-up of 
open-ended questions to identify the participants’ WTP. 
The PC applies a visual scale consisting of a range of 
potential bid values presented to the respondents to indi-
cate their best WTP value [24]. The PC was comprised of 
15 bid values ranging from the lowest US$ 78 to the high-
est US$ 19,381, and we presented the bid to those that 
showed a positive attitude toward the WTP. However, we 
included the values below US$ 78 and above US$ 19,381 
on the PC scale to avoid limiting the participants’ chance 
of not responding.
The follow-up questions elicited the respondents’ exact 
WTP values. We used values ranging from zero to more 
than US$ 19,380 from a pilot study conducted in 2019. 
In this study, we utilized the PC with closed-ended ques-
tions because it covered a wide range of bids and helps 
avoid fatigue and confusion of the respondents in the val-
uations. These limitations are likely to occur when using 
other CVM methods such as the dichotomous choice, 
bidding game formats, and the multiple bounded discrete 
choice methods, where the respondents had to bargain to 
show the WTP values. The value of US$ 1 at the time of 
the study was equivalent to 128,986 Iranian Rials (IRRs) 
[25]. Sociodemographic related variables included in the 
analysis were age, sex, marital status, individual monthly 
income, education status, health insurance coverage, 
birthplace, and having a chronic disease.
Data analysis
We calculated the utility scores from the additional 
QALY gained using the EQ-5D-3L and VAS valuation 
methods. The data were initially scaled on the VAS from 
the best to the worst imaginable health state and then 
rescaling the scores of the respondents from 100 to 0 
using the following formula:
where  VASrchs and  VASraw respectively represent the 
scores of the rescaled current health state and current 
health state.  Deathraw and ′11111′raw are the scores of 
almost dead and perfect health states, respectively.
In this study, the additional QALY gained by each 
respondent was the difference between the utility meas-
ure of the current health state using the EQ-5D-3L or 
VAS and the almost dead health state, and calculated 
using the following mathematical equation:
where  Udeath is the utility from the dead health state 
which is equal to 0.000 and  Uchs is the utility from the 
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gained is the amount of WTP per an additional QALY 
gained by oneself or a family member.
We used the Mann–Whitney and chi-square tests to 
explore the association between the continuous and 
categorical explanatory variables and the WTP for the 
life-saving treatment of the respondents, respectively. 
The data on WTP for the additional QALY gained from 
the life-saving treatment using the EQ-5D-3L and VAS 
methods were positively skewed. Similar to previous 
studies [26–29], we applied the Tobit regression model to 
explore the relationship between the WTP for the addi-
tional QALY gained and the explanatory variables, and 
to handle the possible limitations that may arise when 
using other models. Furthermore, we estimated the mar-
ginal effect of the β∗ and β∗∗ , where β∗ is the explained 
marginal effect for the probability of being uncen-
sored and β∗∗ is the explained marginal effect for the 
expected WTP value conditional on being uncensored: 
E (WTP|WTP > 0). The age, gender, educational level, 
health insurance coverage, marital status, birthplace, 
chronic disease status on oneself, chronic disease status 
in a family member, death of a family member in the past 
year, and monthly household income were the dependent 
variables. The Stata statistical software package version 
14.2 performed all the analyses, and we considered the 
findings as statistically significant at the p-value of less 
than 0.05.
Results
A total sample of 847 adult Iranians aged 18  years and 
above living in Kermanshah city participated in the 
study. The mean age of the participants was 33.6  years, 
with a standard deviation (± SD) of 12.1 years, and male 
and female participants accounted for 45.4% and 54.6%, 
respectively (Table  1). One-hundred and forty-eight of 
the respondents (17.5%) had a monthly income of less 
than US$ 78, while 158 (18.6%) had more than US$ 310 
(US$ 1 = IRR 128,986). Nearly 19% of the respondents 
had chronic diseases, 15.2% had a history of the death of 
a family member in the last year, and around two-thirds 
(65%) were willing to pay for the hypothetical life-saving 
treatment for themselves. The univariate analysis indi-
cated that gender, educational status, health insurance 
coverage, birthplace, and monthly income were statisti-
cally significantly associated with the WTP for the life-
saving treatment.
The pattern of WTP responses
The findings showed a higher mean WTP value for a fam-
ily member (US$ 1,355 ± SD 3,993) than for the individ-
ual participant (US$ 862 ± SD 3,224). About 65% of the 
individual participants had a WTP response (WTP > 0) 
for their own, and the payment rate increased to more 
than 90% WTP > 0 if a family member faced the risk of 
death (Fig.  1). Around 53% of the participants would 
have a WTP value of zero if they would encounter a life-
threatening condition, and 28% would have a WTP value 
of zero if a family member would faced a life-threatening 
situation. In the mid-range of the bid values, the ten-
dency towards paying for the family members was higher, 
but in the upper bid values, the participants showed simi-
lar behavior.
Despite a higher tendency to pay for a family mem-
ber to save a life, there was not a significant difference in 
the WTP pattern. The findings indicated that 75% of the 
respondents had the WTP value of less than US$ 155 for 
themselves, and 59% had the same WTP value as their 
family members. Only 2% of the participants had the 
WTP value of as high as US$19,381 (Fig. 2).
WTP and WTP for additional QALY gained
The annual WTP value for the hypothetical life-saving 
treatment ranged from US$ 0 to 19,381 for the indi-
vidual participants and US$ 0 to 38,763 for their fam-
ily members. There was a slight difference between the 
mean utility value obtained using the EQ-5D-3L method 
and the VAS method (0.779 vs. 0.800). The WTP value 
for one additional QALY gained using the EQ-5D-3L 
method was US$ 1,202, while using the VAS method was 
US$1,101 (Table 2).
Factors affecting WTP per QALY values
The Tobit regression models indicated that the educa-
tional level, gender, birthplace, and monthly income 
were statistically significantly associated (p < 0.05) with 
the WTP for the additional QALY gained using both 
the EQ-5D-3L and the VAS methods (Table 3). Further, 
educational level and monthly income showed a statisti-
cally significant relationship with the WTP for the addi-
tional QALY gained by the family members (p < 0.05). 
The results of the marginal effects of the factors influenc-
ing the WTP revealed that females had a 9.3% and 8.2% 
higher probability of a WTP > $0 for the additional QALY 
gained from the life-saving treatment using the EQ-
5D-3L and VAS methods, respectively than their male 
counterparts (Table 4). The WTP value of females for the 
additional QALY gained was about US$ 515 and US$ 388 
more than the WTP of males using the EQ-5D-3L and 
the VAS methods, respectively.
The findings of the marginal effect analysis using the 
EQ-5D-3L method revealed that the participants with 
moderate-income (US$ 156–310) and those with high 
income (more than US$ 310) respectively had a 11.3 and 
17.5% higher probability of a WTP > $0 for the additional 
QALY gained from the life-saving treatment than those 
with the low income (less than US$ 78). Moreover, the 
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participants with moderate-income and high-income had 
a US$ 641 and US$ 1,044 higher WTP for the additional 
QALY gained from the life-saving treatment, respectively, 
than those with low income.
Discussion
Our findings indicated that the participants’ WTP val-
ues of US$ 1,100 using the VAS method and US$ 1,200 
using the EQ-5D-3L method for the extra QALY gained 
from the hypothetical life-saving treatment. These values 
accounted for 0.20–0.24 of Iran’s GDP per capita in 2019 
(US$ 5,506) and are far lower than the WHO suggested 
CE threshold value of one GDP per capita. The amount 
that the participants were willing to pay for the additional 
QALY gained from the life-saving treatment for a family 
member was about US$ 1,355, which represent 0.27 of 
the GDP per capita. These values are slightly lower than 
the WTP values of 0.22 to 0.56, and 0.57 of the GDP per 
capita for the additional QALY gained findings reported 
from studies in Iran [2, 30]. Comparatively speaking 
other countries such as Thailand found the WTP value of 
1.42 times the GDP per capita for the additional QALY 
gained from life-saving interventions [4]. The strong pos-
itive relationship of the WTP for the extra QALY gained 
with the socioeconomic status of the participants might 
explain the difference.
The lower WTP for the additional QALY gained from 
the life-saving treatment observed in our study may 
Table 1 Frequency distribution, Mann–Whitney and chi-square analysis of willingness to pay for life-saving treatment
SD standard deviation , *p < 0.1 , **p < 0.05 , ***p < 0.01
Variable Willing to pay (n = 551) Not willing to pay 
(n = 296)
n(%) or mean (± SD) p value
Age, in year 32.9 34.7 33.6 (12.1) 0.130
Sex
 Male 233 (42.3%) 152 (51.3%) 385 (45.4%)
 Female 318 (57.7%) 144 (48.6%) 462 (54.6%) 0.012**
Marital status
 Married 121 (40.9%) 235 (42.6%) 356 (42.0%)
 Single 162 (54.7) 294 (53.4%) 456 (53.8%)
 Others 13 (4.4) 22 (4.0%) 35 (4.2%) 0.867
Education status
 Illiterate 26 (4.7%) 21 (7.1%) 47 (5.5%)
 Primary and secondary school 133 (24.1%) 87 (29.4%) 220 (26.0%)
 Academic degree 392 (71.2%) 188 (63.5%) 580 (68.5%) 0.060*
Health insurance coverage
 Yes 438 (79.5%) 205 (69.3%) 643 (75.9%)
 No 113 (20.5%) 91 (30.7%) 204 (24.1%) 0.001***
Birth place
 Urban 458 (83.1%) 218 (73.6%) 679 (79.8%)
 Rural 93 (16.9%) 78 (26.4%) 171 (20.2%) 0.001***
Monthly income US$
 Less than US$ 78 263 (47.7%) 158 (53.4%) 421 (49.7%)
 US$ 78–155 125 (22.7%) 72 (24.3%) 197 (23.3%0
 US$ 156–310 113 (20.5%) 52 (17.6%) 165 (19.5%)
 More than US$ 310 50 (9.1%) 14 (4.7%) 64 (7.6%) 0.008***
Own chronic (long-term) disease
 Yes 101 (18.3%) 58 (19.6%) 159 (18.8%)
 No 450 (81.7%) 238 (80.4%) 688 (81.2%) 0.653
Family member with chronic diseases such as cancer
 Yes 118 (21.4%) 68 (23.0%) 186 (22.0%)
 No 433 (78.6%) 228 (77.0%) 661 (78.0%) 0.602
Family member died in last year
 Yes 82 (14.9%) 47 (15.9%) 129 (15.2%)
 No 469 (85.1%) 249 (84.1%) 718 (84.8%) 0.700
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be due to the declining trend of Iran’s GDP per capita 
in the last few years. For example, the GDP per capita 
decreased from US$ 7,818 in 2011 to US$ 5,506 in 2019 
[31]. The GDP per capita of Iran (US$ 5,506) during the 
current study was also markedly lower than that of Thai-
land (US$ 7,500) in the year 2014, implying that increas-
ing the GDP per capita may contribute to the increase in 
the CE thresholds [12].
Our findings highlight that the WHO CE threshold 
may be unrealistic for use by health policymakers to 
rationally choose cost-effective interventions in low- 
and middle-income countries (LMICs) like Iran, where 
the resources are limited. Others also point out a simi-
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Fig. 1 The rate of responses on each bid value for oneself and for a family member. The less than US$ 78, includes all WTP responses which 



















Fig. 2 The stated WTP amount distribution of oneself and a family member. The less than US$ 78, includes all WTP responses which respondents 
had positive WTP but indicated less than US$ 78
Table 2 Additional QALYs, WTP values and WTP per  QALY 
values
WTP Average ± SD Minimum 
to maximumN = 847
For oneself
 WTP per year ($US) 862 ± 3,224 0–19,381
 Utility value using EQ-5D-3L 0.779 ± 0.168 0.10–0.89
 Utility value using VAS 0.800 ± 0.204 0.11–1
 WTP ($US) per QALY using EQ-5D-3L 1,202 ± 4,991 0–63,819
 WTP ($US) per QALY using VAS 1,101 ± 4,143 0–42,640
For a family member
 WTP per year ($US) 1,355 ± 3,993 0–38,763
 WTP per QALY 1,355 ± 3,993 0–38,763
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choosing a cost-effective treatment is substantially high 
for LMICs [12]. Another possible reason for the differ-
ences in the CE threshold between ours and others might 
be due to the differences in concepts and methods used 
for eliciting the WTP for the additional QALY gained. 
For example, our study depended on the WHO’s recom-
mended CE threshold, which uses income [4], while oth-
ers determined the CE threshold using opportunity costs 
[12] and preference [32]. The use of different scenarios 
such as life-saving treatments, life-prolonging treatment, 
and a difference in study population such as the use of 
the general population and a study on a specific disease 
can lead to differences in the WTP for the additional 
QALY gained. A study in Korea in the general population 
reported that the WTP for an additional QALY from a 
cure was more than twice (KRW 35 million vs. 15 mil-
lion) that of the non-cure [33]. As well, the use of open-
ended questions can be another reason for the difference 
in the WTP values for the extra QALY.
The VAS and EQ-5D-3L methods utilized in our study 
provided almost the same QALY values. Others from 
Thailand also reported closely related mean values for 
the additional QALY gained (0.872 vs. 0.853) using the 
VAS and the EQ-5D-3L methods [4]. The statistically sig-
nificant difference in the WTP for the additional QALY 
for the individual participants and their family members 
observed in our study might relate to the importance of 
family. In a study conducted by Shiroiwa et  al. showed 
that there was a higher QALY value for a family member 
compared to one’s value and indicated it may be because 
of altruistic utility and also the role of family in life [34]. 
Further, our study also showed that monthly income, 
educational level, and sex of the study participant were 
statistically significantly associated with the WTP for the 
extra QALY gained. Others also reported the positive 
association of income with the WTP value [4, 5, 13, 30], 
and higher income and educational level led to a higher 
WTP; and WTP more for the extra QALY gained [33].
Strengths and limitations of the study
This study explored the WTP for the additional QALY 
gained from a hypothetical life-saving treatment and 
provided input for evidence-informed decisions in Iran. 
However, this study has some limitations, and the find-
ings require cautious interpretations. First, the study 
depended on a sample taken from a general population 
in a specific geographic area. Hence, the observed CE 
threshold values cannot be generalizable to the entirety 
of Iran. Second, the study assumed a hypothetical family 
member as a healthy individual with a utility value of one, 
and the actual QALY valuation might not reflect this. 
Finally, the family member was not specified during the 
study period while there could be a wide variation rang-
ing from a child to an elderly person. Thus, future studies 
need to consider these issues and related factors.
Conclusions
The findings revealed that the values of the WTP for the 
additional QALY gained using hypothetical life-saving 
treatment varied from 0.20 to 0.24 of Iran’s GDP per 
capita. These values are far lower than the WHO rec-
ommended CE threshold of one GDP per capita, and 
there existed a strong relationship between the monthly 
income of the study participants and the WTP per capita 
Table 3 Results of  the  Tobit regression analysis 
of the factors affecting on WTP per QALY values
Model A Dependent variable is WTP per QALY using EQ-5D-3L, Model B 
Dependent variable is WTP per QALY using VAS, Model C Dependent variable is 
WTP per QALY for family member
*Significance at p < 0.05
Explanatory variables Model A Model B Model C
β Coefficient β Coefficient β Coefficient
Age, year − 45.0 − 39.4 − 1.3
Sex (ref. male)
 Female 1510.5* 1126.4* 477.7*
Marital status (ref. single)
 Married 335.4 226.5 572.4
 Others 1717.6 479.8 1307.1
Education status (ref. academic degree)
 Illiterate 3351.5* 2162.5* 659.3
 Primary and secondary 
school
− 260.8 − 497.9 − 812.9*
Health insurance coverage (ref. No.)
 Yes 842.9 992.6 − 16.1
Birth place (ref. rural)
 Urban 1398.4* 985.1* 488.2
Monthly income US$ (ref. less than 78)
 US$ 78 – 155 1060.5 506.4 338.9
 US$ 156–310 1849.9* 1064.3* 771.7*
 More than US$ 310 2864.8* 2094.6* 1388.0*
Having chronic disease 
(ref. no.)
 Yes 71.9 418.1 37.1
Family member with chronic diseases such as cancer (ref.no.)
 Yes 670.5 348.3 399.8
Family member died in the last year (ref.no.)
 Yes 563.0 505.8 595.7
 LR chi2 [14] 46.9 38.0 31.0







 Log likelihood − 5785.2 − 5691.8 − 7543.4
Page 8 of 9Moradi et al. Cost Eff Resour Alloc           (2020) 18:47 
values for the additional QALY gained. Future studies 
aiming to elicit the WTP values need to consider differ-
ent scenarios of life-saving interventions to overcome the 
limitations observed in this study.
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Table 4 Marginal effects of factors affecting on WTP per QALY values
Model A Dependent variable is WTP per QALY using EQ-5D-3L, Model B Dependent variable is WTP per QALY using VAS, Model C Dependent variable is WTP per QALY 
for family member, Pr shows the marginal effects for the probability of being uncensored and E indicates the marginal effects for the expected WTP per QALY value 
conditional on being uncensored: E (WTP per QALY | WTP per QALY > 0)
*Significance at p < 0.05
Explanatory variables Model A Model B Model C
Pr E Pr E Pr E
Age, year − 0.003 − 15.5 0.003 − 13.7 − 0.000 − 0.5
Sex (ref. male)
 Female 0.093* 515.1* 0.082* 388.3* 0.043 202.4
Marital status (ref. single)
 Married 0.021 114.6 0.016 78.5 0.052 242.8
 Others 0.106 626.9 0.035 168.7 0.116 583.7
Education status (ref. academic degree)
 Illiterate 0.204* 1334.9* 0.158* 848.5* 0.058 299.8
 Primary and secondary school − 0.016 − 87.2 − 0.036 − 167.8 − 0.071* − 333.9*
Health insurance coverage (ref. No.)
 Yes 0.051 289.4 0.073 344.4 − 0.001 − 6.85
Birth place (ref. rural)
 Urban 0.085* 460.7* 0.072* 330.1* 0.044 203.2
Monthly income US$ (ref. less than 78)
 US$ 78 – 155 0.064 354.1 0.037 171.1 0.031 140.7
 US$ 156–310 0.113* 641.9* 0.078* 371.5* 0.070* 330.4*
 More than US$ 310 0.175* 1044.6* 0.153* 775.9* 0.123* 620.4*
Having chronic disease (ref. no.)
 Yes 0.004 24.7 0.030 145.1 − 0.003 15.8
Family member with chronic diseases such as cancer (ref.no.)
 Yes 0.041 230.2 0.026 120.8 0.036 169.9
Family member died in the last year (ref.no.)
 Yes 0.034 193.3 0.037 175.5 0.054 253.2
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